FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016291232> ?p ?o ?g. }

• W2016291232 endingPage "931" @default.
• W2016291232 startingPage "924" @default.
• W2016291232 abstract "To examine the association between level and patterns of baseline intra-tumoural BRAF(V600E) protein expression and clinical outcome of BRAF(V600E) melanoma patients treated with selective BRAF inhibitors.Fifty-eight BRAF(V600E) metastatic melanoma patients treated with dabrafenib or vemurafenib on clinical trials had pre-treatment tumour BRAF(V600E) protein expression immunohistochemically (IHC) assessed using the BRAF V600E mutant-specific antibody VE1. Sections were examined for staining intensity (score 1-3) and percentage of immunoreactive tumour cells, and from this an immunoreactive score (IRS) was derived (intensity × per cent positive/10). The presence of intra-tumoural heterogeneity for BRAF(V600E) protein expression was also assessed. BRAF(V600E) expression was correlated with RECIST response, time to best response (TTBR), progression-free survival (PFS) and overall survival (OS).Expression was generally high (median IRS 28 (range 5-30)) and homogeneous (78%). Expression of mutated protein BRAF(V600E) as measured by intensity, per cent immunoreactive cells, or IRS did not correlate with RECIST response, TTBR, PFS or OS, including on multivariate analysis. Heterogeneity of staining was seen in 22% of cases and did not correlate with outcome.In the current study population, IHC-measured pre-treatment BRAF(V600E) protein expression does not predict response or outcome to BRAF inhibitor therapy in BRAF(V600E) metastatic melanoma patients." @default.
• W2016291232 created "2016-06-24" @default.
• W2016291232 creator A5001606920 @default.
• W2016291232 creator A5008839819 @default.
• W2016291232 creator A5022520811 @default.
• W2016291232 creator A5035263718 @default.
• W2016291232 creator A5039647180 @default.
• W2016291232 creator A5052657395 @default.
• W2016291232 creator A5057141936 @default.
• W2016291232 creator A5061142461 @default.
• W2016291232 creator A5062978331 @default.
• W2016291232 creator A5071577704 @default.
• W2016291232 creator A5083653505 @default.
• W2016291232 date "2013-02-12" @default.
• W2016291232 modified "2023-10-10" @default.
• W2016291232 title "BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma" @default.
• W2016291232 cites W1566010886 @default.
• W2016291232 cites W1984293031 @default.
• W2016291232 cites W2019607817 @default.
• W2016291232 cites W2040584053 @default.
• W2016291232 cites W2046615229 @default.
• W2016291232 cites W2053473615 @default.
• W2016291232 cites W2056199226 @default.
• W2016291232 cites W2056362223 @default.
• W2016291232 cites W2072313415 @default.
• W2016291232 cites W2076071381 @default.
• W2016291232 cites W2079421845 @default.
• W2016291232 cites W2091100650 @default.
• W2016291232 cites W2106494998 @default.
• W2016291232 cites W2106543129 @default.
• W2016291232 cites W2107693762 @default.
• W2016291232 cites W2128542677 @default.
• W2016291232 cites W2135925159 @default.
• W2016291232 cites W2139248078 @default.
• W2016291232 cites W2166262263 @default.
• W2016291232 cites W2168143310 @default.
• W2016291232 cites W2169614956 @default.
• W2016291232 cites W2171940397 @default.
• W2016291232 cites W2529971012 @default.
• W2016291232 doi "https://doi.org/10.1038/bjc.2013.29" @default.
• W2016291232 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3590666" @default.
• W2016291232 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23403819" @default.
• W2016291232 hasPublicationYear "2013" @default.
• W2016291232 type Work @default.
• W2016291232 sameAs 2016291232 @default.
• W2016291232 citedByCount "53" @default.
• W2016291232 countsByYear W20162912322013 @default.
• W2016291232 countsByYear W20162912322014 @default.
• W2016291232 countsByYear W20162912322015 @default.
• W2016291232 countsByYear W20162912322016 @default.
• W2016291232 countsByYear W20162912322017 @default.
• W2016291232 countsByYear W20162912322018 @default.
• W2016291232 countsByYear W20162912322019 @default.
• W2016291232 countsByYear W20162912322020 @default.
• W2016291232 countsByYear W20162912322021 @default.
• W2016291232 countsByYear W20162912322023 @default.
• W2016291232 crossrefType "journal-article" @default.
• W2016291232 hasAuthorship W2016291232A5001606920 @default.
• W2016291232 hasAuthorship W2016291232A5008839819 @default.
• W2016291232 hasAuthorship W2016291232A5022520811 @default.
• W2016291232 hasAuthorship W2016291232A5035263718 @default.
• W2016291232 hasAuthorship W2016291232A5039647180 @default.
• W2016291232 hasAuthorship W2016291232A5052657395 @default.
• W2016291232 hasAuthorship W2016291232A5057141936 @default.
• W2016291232 hasAuthorship W2016291232A5061142461 @default.
• W2016291232 hasAuthorship W2016291232A5062978331 @default.
• W2016291232 hasAuthorship W2016291232A5071577704 @default.
• W2016291232 hasAuthorship W2016291232A5083653505 @default.
• W2016291232 hasBestOaLocation W20162912321 @default.
• W2016291232 hasConcept C104317684 @default.
• W2016291232 hasConcept C126322002 @default.
• W2016291232 hasConcept C142724271 @default.
• W2016291232 hasConcept C143998085 @default.
• W2016291232 hasConcept C184235292 @default.
• W2016291232 hasConcept C204232928 @default.
• W2016291232 hasConcept C2776131300 @default.
• W2016291232 hasConcept C2776470698 @default.
• W2016291232 hasConcept C2777658100 @default.
• W2016291232 hasConcept C2778472372 @default.
• W2016291232 hasConcept C2778830669 @default.
• W2016291232 hasConcept C2780739268 @default.
• W2016291232 hasConcept C2994587330 @default.
• W2016291232 hasConcept C3019894029 @default.
• W2016291232 hasConcept C501734568 @default.
• W2016291232 hasConcept C502942594 @default.
• W2016291232 hasConcept C55493867 @default.
• W2016291232 hasConcept C57074206 @default.
• W2016291232 hasConcept C71924100 @default.
• W2016291232 hasConcept C86803240 @default.
• W2016291232 hasConcept C95444343 @default.
• W2016291232 hasConceptScore W2016291232C104317684 @default.
• W2016291232 hasConceptScore W2016291232C126322002 @default.
• W2016291232 hasConceptScore W2016291232C142724271 @default.
• W2016291232 hasConceptScore W2016291232C143998085 @default.
• W2016291232 hasConceptScore W2016291232C184235292 @default.
• W2016291232 hasConceptScore W2016291232C204232928 @default.
• W2016291232 hasConceptScore W2016291232C2776131300 @default.
• W2016291232 hasConceptScore W2016291232C2776470698 @default.

• next